Patents by Inventor Michael Mark

Michael Mark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • System And Method To Automatically Triangulate Location Based On Popularity And Density Ranking Of Venues Over Distance
    Publication number: 20130273942
    Abstract: Methods, systems, and computer program products determine, for a number of individuals having a common interest, locations relevant to that common interest. Each individual possesses a user terminal that has a location and executes a messaging application. During the course of a messaging conversation, the application transmits search parameters to a central server. The search parameters may be entered manually or determined automatically by analyzing the conversation. The server identifies clusters of locations that satisfy the search parameters in addition to satisfying geographic proximity to the participants in the conversation. The server scores the clusters, and transmits to the user terminal data relating thereto, for integrated display in the messaging application. Relevant advertising may be identified and transmitted for contemporaneous display.
    Type: Application
    Filed: April 11, 2013
    Publication date: October 17, 2013
    Applicant: Sprylogics International Corp.
    Inventors: Bhavuk Kaul, Aleksandar Zivkovic, Bradley Michael Marks, Marvin Igelman
  • Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
    Patent number: 8551957
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: October 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Michael Mark, Leo Thomas, Frank Himmelsbach
  • Combination therapy for the treatment of diabetes and related conditions
    Patent number: 8513264
    Abstract: The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: August 20, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Mark, Peter Eickelmann, Gerd Luippold, Leo Thomas
  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20130196898
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: November 26, 2010
    Publication date: August 1, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling
  • SUBCUTANEOUS THERAPEUTIC USE OF DPP-4 INHIBITOR
    Publication number: 20130172244
    Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the subcutaneous or transdermal administration of a therapeutically effective amount of a certain DPP-4 inhibitor. The invention further relates to a subcutaneous combination of a certain DPP-4 inhibitor and GLP-1 having a short half life, particularly for reducing weight.
    Type: Application
    Filed: December 27, 2012
    Publication date: July 4, 2013
    Inventors: Thomas KLEIN, Michael MARK
  • XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
    Publication number: 20130165428
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: February 21, 2013
    Publication date: June 27, 2013
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf R.H. LOTZ
  • Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
    Publication number: 20130109703
    Abstract: The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
    Type: Application
    Filed: March 18, 2011
    Publication date: May 2, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Peter Eickelmann, Gerd Luippold, Michael Mark, Leo Thomas
  • INDUCIBLE EXPRESSION OF SGLT5, METHODS AND KITS USING THE SAME
    Publication number: 20130065792
    Abstract: The present invention pertains to the function of SGLT5 as a sodium dependent co-transporter of mannose and/or fructose. The invention provides nucleic acids and host cells for inducible expression of SGLT5. Based on an inducible expression system the invention provides methods, assays and test kits for the identification of compounds interacting with SGLT5, especially with human SGLT5.
    Type: Application
    Filed: March 14, 2012
    Publication date: March 14, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter EICKELMANN, Stefanie FROEHNER, Rolf GREMPLER, Michael MARK
  • LANDSCAPE LIGHTING SYSTEMS
    Publication number: 20130045623
    Abstract: A connector includes a cable tray configured to receive and retain a cable in a stable position and couple with a top cap configured to create an electrical connection with the cable as the top cap is manipulated in a predetermined manner while coupled with the cable tray. An upper surface of the cable tray is configured to receive the cable (e.g., while the cable is generally parallel with the longitudinal axis of the cable tray). The cable tray also includes a finger extending beyond the first end for some distance longitudinally. The finger includes a protrusion that protrudes to some extent in a transverse direction so that a cable-accommodating gap is defined between the protrusion and the first end. The protrusion is configured to bear against the cable and retain the cable in the stable position when the cable is inserted between the protrusion and the first end.
    Type: Application
    Filed: November 22, 2011
    Publication date: February 21, 2013
    Applicant: Lowe's Companies, Inc.
    Inventors: Jean Tuck McGregor, James Michael Broughman, Allen R. Nelson, Darren Michael Mark, Laura Winfield Alexander, Donald Collins Meves
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20130035281
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: February 7, 2012
    Publication date: February 7, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas Klein, Rolf Grempler, Michael Mark
  • Federation of composite applications
    Patent number: 8332459
    Abstract: A predetermined business task of a composite application can be fulfilled. The composite application can include a set of components. The composite application is instantiated by a template means and a predefined collaborative context module controls the interaction of the set of components during the runtime of the composite application. A set of components fulfilling individual services on individual different server systems is leveraged by the composite application. During the instantiation of the composite application from a template, the referenced components (as types) are instantiated leading to runtime instances of these components. The interaction of the different components is controlled on individual different server systems utilizing a primary context module.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: December 11, 2012
    Assignee: International Business Machines Corporation
    Inventors: Michael Blum, Peter Fischer, Hendrik Haddorp, Stefan Hepper, Stefan Liesche, Michael Marks, Thomas Stober
  • Nanoparticles comprising a drug, ethylcellulose, and a bile salt
    Patent number: 8309129
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, ethylcellulose, and a bile salt.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: November 13, 2012
    Assignee: Bend Research, Inc.
    Inventors: Warren Kenyon Miller, Michael Mark Morgen, Daniel Tod Smithey
  • Implicit interaction of portal application components
    Patent number: 8312469
    Abstract: The present invention relates to the field of network portals and in particular to a method and system for exchanging data between components of one or more composite applications implemented on a portal server, wherein the components are programmed independently from each other. An embodiment of the invention includes: automatically intercepting I/O data being input or output respectively to or from the components or a browser; extracting data objects from the I/O data; determining for a source component, which of the data objects match input requirements of which other potential target components; selecting matching data objects for a matching target component; and transferring the matching data objects to the matching target component.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: November 13, 2012
    Assignee: International Business Machines Corporation
    Inventors: Oliver Koeth, Hendrik Haddorp, Stefan Hepper, Stefan Liesche, Michael Marks
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20120283169
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: November 2, 2011
    Publication date: November 8, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rolf GREMPLER, Odd-Eric JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD, Michael MARK
  • Device for Preventing or Ameliorating Seasonal Affective Disorder
    Publication number: 20120271384
    Abstract: An array of blue-emitting LEDs centered at about 460 nm, with a gaussian distribution of plus-or-minus 20 nm. are housed in an elongated housing and powered from a standard USB cable or equivalent DC power source. The user can select between a higher and lower intensity. The blue wavelengths in this range are very effective for cirtopic receptors of the eye, with little impact upon visual receptors (i.e., rod cells and cone cells). This allows optimal therapeutic effect with minimal visual side effects.
    Type: Application
    Filed: October 3, 2011
    Publication date: October 25, 2012
    Inventor: Michael Mark Muehlemann
  • Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
    Publication number: 20120252783
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA & CO. KG
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf LOTZ
  • Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
    Publication number: 20120252782
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf R.H. LOTZ
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Publication number: 20120208831
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: April 17, 2012
    Publication date: August 16, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Frank HIMMELSBACH, Elke LANGKOPF, Matthias ECKHARDT, Michael MARK, Roland MAIER, Ralf R. H. LOTZ, Mohammad TADAYYON
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20120196812
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: April 4, 2012
    Publication date: August 2, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli BROEDL, Rolf GREMPLER
  • Electrical stimulator
    Patent number: D674105
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: January 8, 2013
    Assignee: NDI Medical, LLC
    Inventors: Kenneth P. Rundle, Steven M. Galecki, Michael Marks, Joseph J. Mrva, Jonathan L. Sakai